Less than 1 min.Read

Imugene: Receives FDA approval for PD1-Vaxx trial

November 2, 2020

Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
Then the company gained Investigational New Drug (IND) approval to begin enrolment in a phase one trial in patients with non-small cell lung cancer
The primary aim of the phase one study is to determine the safety and optimal dosage of the drug, as well as measuring efficacy and immune response
PD1-Vaxx is already in phase one clinical trials in Australia
Imugene also cashed up and ready to progress PD1-Vaxx and three other immunotherapies through clinical trials in the current quarter
Imugene is trading grey for 5.6 cents